Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
Duke University · Clinical Research Institute · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
307
total citations
- FWCI
- 43.76
- Percentile
- 100%
- References
- 24
Citations per year
Authors
416- JPJonathan P. PicciniCorresponding
Duke University, Clinical Research Institute, Duke Medical Center
- VCValeria Caso
University of Perugia
- SJStuart J. Connolly
Population Health Research Institute, Hamilton Health Sciences, McMaster University
- KAKeith A.A. Fox
University of Edinburgh
- JOJonas Oldgren
Uppsala University
Topics & keywords
Topics
Keywords
- Apixaban
- Atrial fibrillation
- Medicine
- Double blind
- Internal medicine
- Cardiology
- Gastroenterology
- Surgery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.